References

• 1. Valente NA, Chatelain S, Alfonsi F, Mortellaro C, Barone A. Medication-related osteonecrosis of the jaw. J Craniofac Surg 2019;30:1095–101. doi:10.1097/SCS.0000000000005475 google scholar
• 2. Yazıcı T, Şentürk MF, Koçer G. İlaca bağlı olarak çene kemiklerinde görülen osteonekroz (Mronj):Derleme. SDÜ Sağlık Bil Enst Derg 2017;8(2):50-7. doi:10.22312/sdusbed.302041 google scholar
• 3. Değim T. Bifosfonatlar ve çene kemiğinde kemik erimesi. Ecza Derg 2006;13: 26-8. google scholar
• 4. Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066–72. doi:10.1016/j.eururo.2008.06.070 google scholar
• 5. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA. Incidence of bisphosphonateassociated osteonecrosis of the jaws in breast cancer patients. Cancer 2009;115:1631–37. doi:10.1002/cncr.24119 google scholar
• 6. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving iv bisphosphonates. Oncology 2006;20(9):1053–62. google scholar
• 7. Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the bone study. Osteoporos Int 2004;15:792–8. doi:10.1007/s00198-004-1602-9 google scholar
• 8. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29:1548–58. doi:10.1016/j.clinthera.2007.08.008 google scholar
• 9. Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget’s disease of bone: Indications for treatment and review of current therapies. J Bone Miner Res 2006;21:94–8. doi:10.1359/jbmr.06s218 google scholar
• 10. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res 2007;22:142– 8. doi:10.1359/jbmr.061001 google scholar
• 11. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004;363:1377–85. doi:10.1016/S01406736(04)16051-0 google scholar
• 12. Kamoun-Goldrat A, Ginisty D, Merrer ML. Effect of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 2008;116:195–8. doi: 10.1111/j.16000722.2008.00529.x google scholar
• 13. Duman AE, Güven GS, Gürlek A. Erkek osteoporozu. Hacettepe Tıp Derg 2005;36:175–83. google scholar
• 14. Marx RE. Palmidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. doi:10.1016/ s0278-2391(03)00720-1 google scholar
• 15. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527–34. doi:10.1016/j.joms.2004.02.004 google scholar
• 16. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377:813–22. doi:10.1016/S0140-6736(10)62344-6 google scholar
• 17. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 2003;1:45–52. doi: 10.1007/s11914-003-0008-5 google scholar
• 18. Reszka AA, Rodan GA. Nitrogencontaining bisphosphonate mechanism of action, Mini Rev Med Chem 2004;4:711–9. doi:10.2174/1389557043403648 google scholar
• 19. Stepensky D, Kleinberg L, Hoffman A. Bone as an effect compartment: models for uptake and release of drugs. Clin Pharmacokinet 2003;42:863–81. doi:10.2165/00003088-200342100-00001 google scholar
• 20. Naidu A, Dechow PC, Spears R, Wright JM, Kessler HP, Opperman LA. The effects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:5–13. doi:10.1016/j.tripleo.2008.03.036 google scholar
• 21. Favia G, Pilolli GP, Maiorano E. Histologic and histomorphometric features of bisphosphonaterelated osteonecrosis of the jaws: An analysis of 31 cases with confocal laser scanning microscopy. Bone 2009;45(3):406–13. doi:10.1016/j. bone.2009.05.008 google scholar
• 22. Hinson AM, Smith CW, Siegel ER, Stack BC Jr. Is bisphosphonate-related osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary. Int J Dent 2014;2014:452737. doi:10.1155/2014/452737 google scholar
• 23. Soydan SS, Veziroğlu Şenel F, Araz K. Bifosfonata bağlı olarak çene kemiklerinde gelişen osteonekrozun patogenezi ve tedavisi. Hacettepe Diş Hek Fak Derg 2009;33(3):61-8. google scholar
• 24. Gupta M, Gupta N. Bisphosphonate Related Jaw Osteonecrosis. [Updated 2019 Sep 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. google scholar
• 25. Aghaloo T, Hazboun R, Tetradis S. Pathophysiology of osteonecrosis of the jaws. Oral Maxillofac Surg Clin North Am 2015;27(4):48996. doi:10.1016/j.coms.2015.06.001 2 google scholar
• 6. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66(5):839–47. doi:10.1016/j.joms.2008.01.026 google scholar
• 27. Scoletta M, Arduino PG, Dalmasso P, Broccoletti R, Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110(1):46– 53. doi:10.1016/j.tripleo.2010.02.020 google scholar
• 28. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006 Aug 1;145(3):235]. Ann Intern Med 2006;144(10):753–61. doi:10.7326/0003-4819144-10-200605160-00009 google scholar
• 29. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567–75. doi:10.1016/j.joms.2005.07.010 google scholar
• 30. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353(1):99–102. doi:10.1056/ NEJM200507073530120 google scholar
• 31. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23(34):8580–7. doi:10.1200/ JCO.2005.02.8670 google scholar
• 32. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?. J Oral Maxillofac Surg 2006;64(6):917–23. doi:10.1016/j.joms.2006.02.011 google scholar
• 33. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medicationrelated osteonecrosis of the jaw--2014 update [published correction appears in J Oral Maxillofac Surg. 2015 Jul;73(7):1440] [published correction appears in J Oral Maxillofac Surg. 2015 Sep;73(9):1879]. J Oral Maxillofac Surg 2014;72(10):1938–56. doi:10.1016/j.joms.2014.04.031 google scholar
• 34. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded activecontrolled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23(5): 1341– 7. doi: 10.1093/annonc/mdr435 google scholar
• 35. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14(9): 901-8. doi: 10.1016/S14702045(13)70277-8 google scholar
• 36. Colella G, Campisi G, Fusco V. American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 2009;67(12):2698–9. doi:10.1016/j. joms.2009.07.097 google scholar
• 37. Vassiliou V, Tselis N, Kardamakis D. Osteonecrosis of the jaws: clinicopathologic and radiologic characteristics, preventive and therapeutic strategies. Strahlenther Onkol 2010;186(7):367– 73. doi:10.1007/s00066-010-2066-9 google scholar
• 38. Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, et al. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig 2010;14(3):311–7. doi:10.1007/s00784-009-0293-1 google scholar
• 39. Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli F, Di Lenarda R. Bone scintigraphy and SPECT/ CT of bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med 2009;50(1):30–5. doi:10.2967/ jnumed.107.048785 google scholar
• 40. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(4):433–41. doi:10.1016/j.tripleo.2006.06.004 google scholar
• 41. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134(6):620–3. doi:10.1111/j.1365-2141.2006.06230.x google scholar
• 42. Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, et al. Bisphosphonate related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol 2007;18(6):168–72. doi:10.1093/annonc/mdm250 google scholar
• 43. Hino S, Murase R, Terakado N, Shintani S, Hamakawa H. Response of diffuse sclerosing osteomyelitis of the mandible to alendronate: follow-up study by 99mTc scintigraphy. Int J Oral Maxillofac Surg 2005;34(5):576–8. doi:10.1016/j. ijom.2005.01.003 google scholar
• 44. van der Waal RI, Buter J, van der Waal I. Oral metastases: report of 24 cases. Br J Oral Maxillofac Surg 2003;41(1):3–6. doi:10.1016/ s0266-4356(02)00301-7 google scholar
• 45. Marx RE. Oral and intravenous bisphosphonate induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. 2nd ed. Quintessence Pub Co; 2011. google scholar
• 46. Karaçelebi E, Öztürk M. Oral ve maksillofasial cerrahide bifosfonatlar ve bifosfonatlar ilişkili çene osteonekrozu tedavisinde yeni yaklaşımlar. ADO Klin Bil Derg 2012(5): 1052–62. google scholar
• 47. Perini AT, de Oliveira GR, Seguin F. Medicationrelated osteonecrosis of the jaw (MRONJ) treated with piezosurgery – case report and review of literature. RSBO 2018;15(2):123-9. doi: 10.21726/rsbo.v15i2.679 google scholar
• 48. Merigo E, Cella L, Oppici A, Cristina Arbasi M, Clini F, Fontana M, et al. Combined Approach to Treat Medication-Related Osteonecrosis of the Jaws. J Lasers Med Sci 2018;9(2):92-100. doi: 10.15171/jlms.2018.19. google scholar
• 49. Phal PM, Myall RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. Am J Neuroradiol 2007;28:1139–45. doi: 10.3174/ajnr.A0518 google scholar
• 50. Berg BI, Mueller AA, Augello M, Berg S, Jaquiéry C. Imaging in Patients with BisphosphonateAssociated Osteonecrosis of the Jaws (MRONJ). Dent J (Basel) 2016;4(3):29. doi:10.3390/dj4030029 google scholar
• 51. Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J Int Soc Prev Community Dent 2016;6(2):97‐104. doi:10.4103/2231-0762.178742 google scholar
• 52. Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int 2018;2018:2684924. doi: 10.1155/2018/2684924. google scholar
• 53. Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. MedicationRelated Osteonecrosis of the Jaw: MASCC/ ISOO/ASCO Clinical Practice Guideline. J Clin Oncol 2019;37(25):2270–90. doi:10.1200/ JCO.19.01186 google scholar
• 54. Öztürk E, Saruhan N. İlaca bağlı olarak çene kemiklerinde görülen osteonekroz (Mronj): Derleme. J BHSR 2019;3(1):8-20. doi: 10.34084/ bshr.535974 google scholar
• 55. Favia G, Piattelli A, Sportelli P, Capodiferro S, Iezzi G. Osteonecrosis of the posterior mandible after implant insertion: a clinical and histological case report. Clin Implant Dent Relat Res 2011;13(1):58–63. doi:10.1111/j.17088208.2009.00181.x google scholar
• 56. Lazarovici TS, Yahalom R, Taicher S, SchwartzArad D, Peleg O, Yarom N. Bisphosphonaterelated osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010;68(4):790–6. doi:10.1016/j. joms.2009.09.017 google scholar
• 57. Shirota T, Nakamura A, Matsui Y, Hatori M, Nakamura M, Shintani S. Bisphosphonaterelated osteonecrosis of the jaw around dental implants in the maxilla: report of a case. Clin Oral Implants Res 2009;20(12):1402–8. doi:10.1111/j.1600-0501.2009.01801.x google scholar
• 58. Walter C, Al-Nawas B, Wolff T, Schiegnitz E, Grötz KA. Dental implants in patients treated with antiresorptive medication - a systematic literature review. Int J Implant Dent 2016;2(1):9. doi:10.1186/s40729-016-0041-7 google scholar
• 59. Freiberger JJ, Padilla-Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 2012;70(7):1573–83. doi:10.1016/j.joms.2012.04.001 google scholar
• 60. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc 2007;138(7):971–7. doi:10.14219/ jada.archive.2007.0294 google scholar
• 61. Erkan M, Bilgi O, Mutluoğlu M, Uzun G. Bisphosphonate-related osteonecrosis of the jaw in cancer patients and hyperbaric oxygen therapy. JOP 2009;10(5):579–82. google scholar
• 62. Momesso GAC, de Souza Batista FR, de Sousa CA, de Lima VN, Polo TOB, Hassumi JS, et al. Successful use of lower-level laser therapy in the treatment of medication-related osteonecrosis of the jaw. J Lasers Med Sci 2017;8(4):201–3. doi:10.15171/jlms.2017.37 google scholar
• 63. Sarkarat F, Modarresi A, Chiniforush N, Yazdanparast L, Rakhshan V. Efficacy of photodynamic therapy in minimizing bisphosphonate-related osteonecrosis of the jaws after dental extraction: A preliminary animal study. J Oral Maxillofac Surg 2019;77(2):307–14. doi:10.1016/j.joms.2018.09.036 google scholar
• 64. Cicciù M, Herford AS, Juodžbalys G, Stoffella E. Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw. J Craniofac Surg 2012;23(3):784–8. doi:10.1097/SCS.0b013e31824dbdd4 google scholar
• 65. Curi MM, Cossolin GS, Koga DH, Zardetto C, Christianini S, Feher O, et al. Bisphosphonaterelated osteonecrosis of the jaws-an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg 2011;69(9):2465– 72. doi:10.1016/j.joms.2011.02.078 google scholar
• 66. Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonateassociated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110(5):593–6. doi:10.1016/j.tripleo.2010.05.067 google scholar

Citations